Clinical Compound Library Plus | 临床化合物库 Plus | MedChemExpress (MCE)
品牌 | 厂商性质 | 产地 | 货期 |
---|---|---|---|
MedChemExpress (MCE) | 生产商 | 美国 | 现货 |
性能特点
New drug development is a time-consuming and high-cost process. Drug repurposing (also called dr
New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or re‑tasking) offers various advantages over developing an entirely new drug for a given indication, such as lower risk and less investment. Clinical drugs have confirmed bioactivities, clear mechanisms and high safety that are suitable for drug repurposing. MCE owns a unique collection of 3,079 clinical compounds that refer to various research areas including anti-cancer, anti-infection, anti-inflammation, nervous disease. Those compounds are of detailed information on clinical development status, research area, targets, etc. Clinical Compound Library Plus, with powerful screening capability, further complements Clinical Compound Library (HY-L026) by adding some compounds with low solubility or solution stability (Part B) to this library. All those supplementary are supplied in powder form.更多产品详情查看:www.medchemexpress.cn/screening/clinical-compound-library-plus.html
Clinical Compound Library Plus | 临床化合物库 Plus | MedChemExpress (MCE)信息由MedChemExpress (MCE)为您提供,如您想了解更多关于Clinical Compound Library Plus | 临床化合物库 Plus | MedChemExpress (MCE)报价、型号、参数等信息,欢迎来电或留言咨询。
注:该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案,不可用于临床诊断或治疗等相关用途